Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140153 | 0.87 | PDE2A (0.32) | TOP2ATOP2BPDE2AALDH1A1HSP90AA1 | |
| SCHEMBL20139430 | 0.84 | EPHX2 (0.33) | TOP2ATOP2BPDE2AALDH1A1HSP90AA1 | |
| SCHEMBL20140293 | 0.83 | TOP2A (0.36) | TOP2ATOP2BHTR2CHTR2AHTR2B | |
| SCHEMBL20139978 | 0.79 | TOP2A (0.41) | TOP2ATOP2BHTR2CHTR2AHTR2B | |
| SCHEMBL20139480 | 0.78 | CHRNA7 (0.44) | TOP2ATOP2BHTR2CHTR2AKMT2A | |
| SCHEMBL20140072 | 0.76 | KMT2A (0.40) | TOP2ATOP2BALDH1A1HSP90AA1GAA | |
| SCHEMBL20140209 | 0.71 | SLC5A1 (0.45) | HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL20140114 | 0.70 | TOP2A (0.37) | TOP2ATOP2BALDH1A1 | |
| SCHEMBL20140089 | 0.69 | TOP2A (0.38) | TOP2ATOP2BALDH1A1 | |
| SCHEMBL12782153 | 0.67 | LMNA (0.46) | TOP2ATOP2BPDE2AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | TOP2A 2707/4885TOP2B 2772/4885HTR2C 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.